Can CMR Elucidate the Cardiovascular Benefit of SGLT2 Inhibitors?

Stephen J. Nicholls; Nitesh Nerlekar

doi:10.1016/j.jcmg.2020.11.003

Can CMR Elucidate the Cardiovascular Benefit of SGLT2 Inhibitors?

Medicine Monash Health

Research output: Contribution to journal › Editorial › Other › peer-review

Original language	English
Pages (from-to)	1174-1176
Number of pages	3
Journal	JACC: Cardiovascular Imaging
Volume	14
Issue number	6
DOIs	https://doi.org/10.1016/j.jcmg.2020.11.003
Publication status	Published - Jun 2021

Keywords

cardiovascular
clinical trials
CMR
interstitial
SGLT2 inhibitors

Access to Document

10.1016/j.jcmg.2020.11.003

Cite this

@article{7b546383ee2c4dcf82c0c5a01d880137,

title = "Can CMR Elucidate the Cardiovascular Benefit of SGLT2 Inhibitors?",

keywords = "cardiovascular, clinical trials, CMR, interstitial, SGLT2 inhibitors",

author = "Nicholls, \{Stephen J.\} and Nitesh Nerlekar",

year = "2021",

month = jun,

doi = "10.1016/j.jcmg.2020.11.003",

language = "English",

volume = "14",

pages = "1174--1176",

journal = "JACC: Cardiovascular Imaging",

issn = "1936-878X",